Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Histamine dihydrochloride is the hydrochloride salt of histamine, a biogenic amine with immunomodulatory and antineoplastic properties. It is used as an adjunct in the prevention of relapse in patients with acute myeloid leukemia (AML), particularly in combination with low-dose interleukin‑2 (IL‑2) during post-remission maintenance therapy. The drug acts by inhibiting reactive oxygen species formation via histamine H2 receptors on monocytes, thereby protecting natural killer and T cells from oxidative damage and enhancing immune-mediated killing of leukemic cells. In addition to its oncological use, it is also an FDA-approved active ingredient for topical analgesic products intended for temporary relief of minor muscle and joint pain associated with arthritis, backache, bruises, sprains, or strains[1][2][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on histamine dihydrochloride.